On February 7, the seventh day of the first month, the lunar year of the tiger officially opened! A new opportunity has come!
According to the current arrangement, six new shares of A-Shares will be issued in the week from February 7 to February 11, including Hualan vaccine, the leading stock of vaccine, which will be listed on the gem, and the partnership under Gaoling, headed by well-known investor Zhang Lei, holds 9%; Hualan vaccine is also a holding subsidiary of biomedical leader Hualan Biological Engineering Inc(002007) .
There are 6 new shares issued on the main board of Kechuang, including 3 new shares issued on the main board of Kechuang this week. In addition to the Hualan vaccine on the gem, the advertised shares on the gem, Hefu China, Biyi shares, Jinhui shares on the main board of the Shanghai Stock Exchange, and the medium catalyst of the science and innovation board.
Hillhouse has issued new shares, and Tencent has also participated in
Hualan vaccine, a new share of gem issued on Tuesday, February 8, is the focus of this week’s new shares and the leading stock of family vaccine. Hualan Biological Engineering Inc(002007) is a high-tech enterprise specializing in the R & D, production and sales of human vaccines. The company’s main products are human vaccines, and the listed products can be divided into viral vaccines, bacterial vaccines and gene recombinant vaccines.
It is worth noting that Hualan vaccine not only has a controlling shareholder Hualan Biological Engineering Inc(002007) with a market value of 46 billion, but also Zhang Lei’s high position and Tencent’s figure in the list of shareholders.
The issuance price of Hualan vaccine has not been announced yet. The upper limit of online subscription is 6500 shares. Dingge subscription needs to hold a market value of 65000 yuan in Shenzhen. Hualan Biological Engineering Inc(002007) is the controlling shareholder of the company, with a shareholding ratio of 75%. In addition, Hong Kong Kekang holds 10% of the company’s shares, Gaoling Huaying holds 9% of the company’s shares, and Chenyi Qiming holds 6% of the company’s shares.
Tianyan check shows that the three shareholders of Gaoling Huaying are Shenzhen Gaoling Tiancheng phase III Investment Co., Ltd., Shenzhen Gaoling Muqi equity investment fund partnership (limited partnership) and Shenzhen Gaoling Kunqi equity investment fund partnership (limited partnership). Among them, Shenzhen hilling Muqi equity investment fund partnership (limited partnership) holds nearly 90% of the shares, and the largest shareholder of the enterprise is Shenzhen Tencent industrial investment fund Co., Ltd., holding 34.18%.
During the reporting period, the company’s main business products include influenza virus split vaccine, tetravalent influenza virus split vaccine, influenza A H1N1 virus split vaccine, acyw135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansen’s yeast), group A and group C meningococcal polysaccharide vaccine. From 2018 to 2020, the company achieved operating revenue of 802738200 yuan, 1048988200 yuan and 2426328900 yuan respectively, with a compound growth rate of 73.86%; The company’s influenza vaccine sales revenue was 697341700 yuan, 1042917400 yuan and 2421827700 yuan respectively, accounting for 86.87%, 99.42% and 99.81% of the company’s operating revenue, which is the main source of the company’s operating revenue.
Low price stocks of 4 yuan have also attracted attention
In addition to the Hualan vaccine supported by well-known institutions, in the case of frequent breaking of new shares, low-cost new shares Hefu China are also concerned, and low-cost stocks often have great upward explosive power.
Hefu China, the main board of Shanghai Stock Exchange, has an issue price of 4.19 yuan and an issue P / E ratio of 22.99 times, which is 18.65 times higher than the industry’s average static P / E ratio in the latest month.
The data show that the main board with low issuance price often has a good performance after the listing of new shares. For example, China Southern Power Grid Energy Efficiency&Clean Energy Co.Ltd(003035) , Huitong group, Changchun Engley Automobile Industry Co.Ltd(601279) , Caida Securities Co.Ltd(600906) , Chutian Dragon Co.Ltd(003040) , China National Gold Group Gold Jewellery Co.Ltd(600916) and other stocks listed last year with an issue price of less than 5 yuan have gained more than 10 trading boards in a row.
Huitong group, listed on the main board of Shanghai stock market on December 31, 2021, has an issue price of 1.7 yuan, and has pulled 17 daily limit boards after listing.
Hefu China is a channel provider in the field of medical circulation, and has the core competitiveness of long-term mutual benefit and win-win cooperation with domestic and foreign reagent consumables and medical equipment manufacturers, major agents and medical institutions. At present, the main business is intensive business of in vitro diagnostic products, circulation of medical products and other value-added services.
The company’s medical product circulation business is mainly to act as an agent for the original equipment of foreign Innovation Medical Management Co.Ltd(002173) technology, mainly for medical institutions in Greater China. The company has established a perfect customer service network in China and accumulated rich customer resources. The main customers include a large number of large well-known public hospitals, such as Shanghai first maternal and child health hospital, Affiliated Hospital of Jining Medical College, Shengli Oilfield Central Hospital, Shanghai Tenth People’s Hospital, Zhenjiang first people’s Hospital, Shanghai public health clinical center and so on.
In addition, China catalyst is the leader of China’s special catalyst, with an issue price of 41.90 yuan / share, an issue P / E ratio of 85.98 times, and a reference Industry P / E ratio of 42.78 times. Dingge’s subscription needs to be matched with a market value of 110000 yuan in Shanghai. China catalyst plans to raise 784 million yuan this time, while the actual net fund-raising reaches 1.691 billion yuan, and the over raising multiple is 2.16 times.
According to the data, China catalyst is mainly engaged in the R & D, production and sales of special molecular sieves and new catalytic materials, as well as chemical technology and chemical process services. In terms of performance, during the reporting period (January September of 2018, 2019, 2020 and 2021), the company realized net profits of 09 million yuan, 53 million yuan, 92 million yuan and 116 million yuan respectively. The company expects to achieve a net profit of 124 million yuan to 144 million yuan in 2021, an increase of about 35.02% to 56.80% over 2020.
Biyi Co., Ltd. is an enterprise mainly engaged in the design, manufacturing and sales of heating kitchen electrical products. The company’s main business mainly includes ODM / OEM business and “Biyi Biyi” independent brand OBM business. At present, it has cooperated with Philips / Philips, Newell / newway brand, sharkninja / shankoningjia, Delonghi group / Delong company, SEB / Saibo group, Bear Electric Appliance Co.Ltd(002959) Zhejiang Supor Co.Ltd(002032) and other foreign customers.
The main business of flaunting shares is the R & D, production and sales of a series of products such as automobile nylon pipes and connectors. The main products include power system connecting pipes. As one of the few advantageous enterprises in China that have entered the supply system of joint venture brand vehicle manufacturers, the company’s main products have been widely matched with many models of well-known brands such as Volkswagen, Audi, Skoda, Datong, Ford and Peugeot, and has established stable strategic cooperative relations with well-known vehicle manufacturers and excellent auto parts manufacturers in China, It has a high brand awareness and industry position in the automobile nylon pipeline manufacturing industry.
Jinhui Co., Ltd. is mainly engaged in the mining, beneficiation and trade of non-ferrous metals. Its main products include zinc concentrate, lead concentrate (including silver), etc. The mining rights include two mining rights of Guojiagou lead-zinc mine in Huixian county and the lead-zinc mine in the eastern section of the North ore belt in the South ore belt of Guojiagou mining area in Huixian County, as well as the detailed survey of lead-zinc mine in Jiangkou area of Huixian County, Gansu Province and huomadi copper mine in Qinzhou District, Tianshui City, Gansu Province. In addition, it owns Lijiagou concentrator.
The first wave of new shares in the year of the tiger is coming! Audi, Volkswagen, Ford and Peugeot all have it
Six new shares in the first week of the year of the tiger! Influenza vaccine leaders are about to land on the gem, and suppliers of Audi, Volkswagen, Ford and Peugeot are also coming
